Patients characteristic | Cases | Controls | Overall | p | |||
---|---|---|---|---|---|---|---|
(n = 18) | (n = 18) | (n = 36) | |||||
n | (%) | n | (%) | n | (%) | ||
T (primary) | |||||||
1 | 9 | (50.0) | 9 | (50.0) | 18 | (50.0) | |
2 | 8 | (44.4) | 8 | (44.4) | 16 | (44.4) | |
3 | 1 | (5.6) | 1 | (5.6) | 2 | (5.6) | |
N (positive lymph-nodes) | |||||||
0 | 6 | (33.3) | 6 | (33.3) | 12 | (33.3) | |
1 | 5 | (27.8) | 5 | (27.8) | 10 | (27.8) | |
2 | 4 | (22.2) | 4 | (22.2) | 8 | (22.2) | |
3 | 3 | (16.7) | 3 | (16.7) | 6 | (16.7) | |
Stage at diagnosis | |||||||
I | 4 | (22.2) | 4 | (22.2) | 8 | (22.2) | |
II | 7 | (38.9) | 7 | (38.9) | 14 | (38.9) | |
III | 7 | (38.9) | 7 | (38.9) | 14 | (38.9) | |
Luminal | |||||||
A | 12 | (66.7) | 12 | (66.7) | 24 | (66.7) | |
B | 6 | (33.3) | 6 | (33.3) | 12 | (33.3) | |
Grading | 0.5361 | ||||||
1 | 2 | (11.1) | 2 | (11.1) | 4 | (11.1) | |
2 | 9 | (50.0) | 12 | (66.7) | 21 | (58.3) | |
3 | 7 | (38.9) | 4 | (22.2) | 11 | (30.6) | |
Adjuvant CT | 0.4088 | ||||||
No | 6 | (33.3) | 4 | (22.2) | 10 | (27.8) | |
Antracycline | 5 | (27.8) | 3 | (16.7) | 8 | (22.2) | |
Antracycline + taxanes | 7 | (38.9) | 11 | (61.1) | 18 | (50.0) | |
Adjuvant HT | 0.2146 | ||||||
No | 1 | (5.9) | 0 | (0) | 1 | (2.9) | |
Tamoxifen ± LHRH an | 8 | (47.1) | 3 | (16.7) | 11 | (31.4) | |
Letrozol | 5 | (29.4) | 10 | (55.5) | 15 | (42.9) | |
Anastrozol | 3 | (17.6) | 4 | (22.2) | 7 | (0.2) | |
Sequence of HT | 0 | (0) | 1 | (5.6) | 1 | (0.03) | |
mean | sd | mean | sd | mean | sd | ||
Age (years) | 64.5 | 16.7 | 64.3 | 14.1 | 64.4 | 11.7 | 0.9554 |